Banxico Cuts 2025 Growth Forecast to 0.1% and to 0.9% for 2026
Mexico's central bank lowered its growth forecasts for this year and next amid mounting signs that Latin America's second-biggest economy is stalling.
Banxico, as the bank is known, cut its 2025 gross domestic product growth forecast to 0.1% in its central scenario, from 0.6% previously, according to the presentation of its quarterly inflation report. The bank sees the economy growing 0.9% next year, from the 1.8% estimate in February's report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Don't regulate us like radio, music streamer Spotify tells CRTC
OTTAWA — Music streamer Spotify says Canada's federal broadcast regulator shouldn't impose rules meant for radio on streaming services. Appearing before a CRTC hearing today, company representatives compared regulating Spotify like a radio station to treating Uber like a horse and buggy. In its written submission, Spotify argued the CRTC doesn't have the jurisdiction to extend rules governing commercial negotiations and disputes in the broadcast sector to online players. The CRTC is holding a hearing on market dynamics as part of its work to implement the Online Streaming Act, which updated broadcasting laws to capture online platforms. During previous hearings, large cable and broadcasting companies like Bell and Rogers called on the CRTC to loosen existing rules for traditional players. They're taking aim at regulations governing how cable channels must be packaged and disputes about carriage of cable channels. This report by The Canadian Press was first published June 20, 2025. Anja Karadeglija, The Canadian Press
Yahoo
30 minutes ago
- Yahoo
Eli Lilly (NYSE:LLY) Faces $7 Billion Lawsuit While Partnering With Innovative Biotech
Eli Lilly has been in the spotlight recently with a 3.96% share price increase over the past month. The selection of RyboDyn Inc. to join Lilly Gateway Labs stands out among recent developments, signaling strengthened research capabilities in precision immunotherapies and potentially bolstering investor confidence. Additionally, the company's legal entanglement with the lawsuit concerning Actos, following a class certification affirmation, highlights ongoing challenges in the pharmaceutical sector. The company's ongoing talks to acquire Verve Therapeutics also show its commitment to growing its gene-editing capabilities. These events have added weight to the broader market's trends. We've identified 2 warning signs for Eli Lilly (1 can't be ignored) that you should be aware of. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. Recent developments at Eli Lilly, such as the RyboDyn Inc. collaboration, have potential implications for its strategic growth, particularly in precision immunotherapies. This aligns with the company's narrative of expanding capabilities in oncology and immunology, indicating possible enhancements in revenue and earnings forecasts over the long term. Additionally, as Eli Lilly progresses with Phase III trials, including those for orforglipron, the anticipated product approvals could bolster revenue avenues by tapping into high-demand markets like diabetes and obesity treatments. Over the past five years, Eli Lilly's total shareholder return was a very large 430.14%, demonstrating substantial long-term growth despite recent underperformance against the US Pharmaceuticals industry, which saw a 8.9% drop over the past year. This impressive five-year return provides context to the company's current position, underscoring a history of robust shareholder value creation. Given the ongoing acquisition talks with Verve Therapeutics and Eli Lilly's significant investment in both manufacturing and R&D, the outlook for future revenue and earnings remains optimistic. However, potential regulatory hurdles and pricing pressures, particularly in the U.S. market, highlight possible challenges. The shares, with a current price of US$775.12, are 21.0% below the analyst consensus target of US$981.63. This discount suggests room for growth, should the company meet or exceed the analyst expectations on revenue and earnings. Learn about Eli Lilly's future growth trajectory here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:LLY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
32 minutes ago
- Yahoo
How Advisors Can Avoid Becoming Over-Reliant on AI
Apparently there's no AI in team. Artificial intelligence is being hailed as a key element of the fourth industrial revolution, and new tools are now assisting financial advisors with taking notes, drafting emails, and brainstorming thought leadership content. In fact, the vast majority of advisors said generative AI helped their practices, according to a survey earlier this year. But AI isn't a silver bullet. It lacks emotional intelligence and a human touch. Advisors risk damaging client relationships if they become too reliant on automation — even for routine tasks. 'AI is poor at empathy so far,' said Adrian Johnstone, CEO of the CRM platform Practifi. 'Advisors need to recognize where the personal connection is most powerful, and use AI to automate and alleviate the lesser functions.' READ ALSO: What the GENIUS Act Means for Stablecoins and Advisors and Why UBS Is the Only Wirehouse to Allow Podcasting Today, most advisors use AI to boost meeting efficiency and streamline workflows. Ideally, this frees up more time to spend with clients, but misusing these tools can backfire. 'The common refrain of disaffected clients is: 'I pay you to understand me, my goals, and my fears, not to outsource me to a machine,'' Johnstone said. Wealth management is built on bespoke service, but AI hasn't yet learned to fully adapt to individual client needs and goals. While tools that draft emails and website content are improving, the output still reads 'hollow and generic,' Johnstone warned. Use it or Lose it. Client-facing AI tools can be 'extremely risky' because they can't interpret emotional undertones of client's concerns, said Rafael Loureiro, CEO of an estate planning platform. Still, AI can be useful for quick, factual tasks. 'If it's midnight on a Sunday and a client asks, 'What was my marginal tax rate last year?' that's a perfect use case,' Loureiro said. 'It's not doing financial planning, but answering factual questions.' Everything in Moderation. This isn't the first time new tech or strategies meant to disrupt the wealth management industry have wound up causing trouble for advisors and their clients. Will Trout, director at Datos Insights, pointed to the 2008 financial crisis as a warning. 'Firms that over-relied on risk models without human oversight suffered catastrophic losses,' he told Advisor Upside. This post first appeared on The Daily Upside. To receive financial advisor news, market insights, and practice management essentials, subscribe to our free Advisor Upside newsletter. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
